Davion HealthCare Confirms October 22 Nasdaq Trading Date and £30 Million Bond Launch

Davion HealthCare Plc expects its ordinary shares to begin trading on the Nasdaq Global Market on October 22, 2026, under the ticker DAVI, and has launched a £30 million five-year senior secured bond to fund acquisitions, Stock Titan reported. The Irish digital healthcare company develops non-invasive health monitoring technologies.

Davion HealthCare's Nasdaq Debut and Bond Launch

Davion HealthCare designs, develops and commercialises non-invasive health monitoring technologies intended to make it easier for individuals to monitor their health outside traditional clinical environments. Its flagship product is BreastCheck, an FDA-registered, non-invasive at-home breast health screening test designed to identify potential abnormalities through changes in breast temperature. The test can be completed at home in less than 15 minutes, with results available through a mobile app or online. BreastCheck is intended to support proactive breast health monitoring and is not a replacement for mammography or clinical diagnosis. The expected commencement of trading comes during Breast Cancer Awareness Month, as Davion advances the commercialisation and distribution of BreastCheck in the United States and internationally.

Maxim Group LLC acted as financial advisor to the Company in connection with the Nasdaq listing. Maxim Group initiated coverage on Kyntra Bio with a buy rating and $35 target, according to Markets Daily.

Davion HealthCare's Funding and Acquisition Record

According to akta.pro company records, Davion HealthCare has one funding round on record, a 2026-09 debt-funded round of $40.4 million. The company entered a share purchase agreement to acquire 100% of Humanoskan Ltd, a medical-technology IP company, for $60 million total consideration, comprising $10 million cash plus $50 million in Davion ordinary shares at $13.00 per share. It also announced a proposed corporate bond programme of up to £100 million across three series with a 10.5% fixed coupon and five-year maturity, to be listed on the Vienna Stock Exchange MTF platform with an expected August 2026 launch via new wholly-owned subsidiary Davion Healthcare Finance Ltd.

Earlier Moves Toward the Listing

In September 2026, Davion Healthcare Finance Ltd admitted a £30 million senior secured bond to trading on the Vienna MTF, with a five-year term and 10.5% fixed coupon, and proceeds will fund acquisitions of healthcare businesses across medical devices, diagnostics, and related sectors, PR Newswire reported. In June 2026, Davion Healthcare Plc entered into a share purchase agreement to acquire 100% of the issued share capital of medical technology company Humasikan Ltd for total consideration of $60 million, comprising $10 million in cash and $50 million through the issuance of Davion ordinary shares at a reference price of $13.00 per share, Aijourn reported. Also in June 2026, Davion Healthcare Plc announced it is transitioning to a direct commercialization model, terminating its existing global licensing and distribution arrangements for Davion BreastCheck, while simultaneously entering an agreement to acquire a controlling interest in Solar Medical and Chemical Limited, a UK-based medical products distribution business, PR Newswire reported.

Leadership Changes at Trading Commencement

Glenn Williams will be appointed Chief Executive Officer and Jeremy North Chief Operating Officer, with both appointments taking effect upon commencement of trading on Nasdaq. The current Chief Executive Officer, Jack Kaye, will become Chairman upon commencement of trading, continuing to provide strategic guidance to the Group and its Board. Sir Eric Peacock will step down as Chairman and will remain on the Board as a Non-Executive Director. The Company is establishing an Operational Directorate as its principal executive management body, led by Chief Executive Officer Glenn Williams, to include the Chief Financial Officer, Chief Operating Officer and Chief Commercial Officer.